In a post-budget briefing, Union Minister Dr. Jitendra Singh underscored the government’s vision for enduring growth through the latest Union Budget. He emphasized that initiatives like affordable medications, supported by domestic biomanufacturing of vaccines and diagnostics, will directly uplift the middle and vulnerable classes.
The budget, Dr. Singh said, reflects a methodical approach where reforms harness state-of-the-art tech propelled by AI. It shifts focus from immediate fiscal perks to curbing rising expenses in health and daily life, a move tailored for the middle class.
Key highlights include substantial funding for biopharma sectors targeting chronic conditions. Families grappling with diabetes—affecting 11-12 crore people, plus 14 crore pre-diabetics—and rapidly rising cancer rates will see relief. Projections warn of 20 lakh cancer cases yearly by 2030, making these investments critical.
India’s emergence as a top global and Indo-Pacific bio-economy leader gets a boost from the Rs 10,000 crore scheme. It will enhance production of biologics, vaccines, and gene therapies, cementing the nation’s manufacturing prowess.
Dr. Singh envisioned biotechnology as the next IT-like powerhouse, fueling a bio-industrial revolution centered on sustainability and life sciences. The budget’s inclusion of non-communicable diseases and mental health marks a milestone, with planned super-specialty centers in North India and new Ayurveda-pharma institutes blending tradition with innovation for comprehensive healthcare access.